Treace Medical Concepts, Inc. Research and Development Expense
Treace Medical Concepts, Inc. (TMCI) reported Research and Development Expense of $4.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- Treace Medical Concepts, Inc. research and development expense for the quarter ending 2026-06-30 was $4.38M, a 20.41% decline year-over-year.
- Treace Medical Concepts, Inc. research and development expense for the quarter ending 2026-03-31 was $4.62M, a 16.90% decline year-over-year.
- Treace Medical Concepts, Inc. research and development expense for the quarter ending 2025-12-31 was $4.54M, a 12.82% decline year-over-year.
- Treace Medical Concepts, Inc. research and development expense for the quarter ending 2025-09-30 was $4.68M, a 5.70% decline year-over-year.
- Treace Medical Concepts, Inc. research and development expense for fiscal 2025 was $20.28M, a 1.49% decline from fiscal 2024.
- Treace Medical Concepts, Inc. research and development expense for fiscal 2024 was $20.59M, a 33.35% increase from fiscal 2023.
- Treace Medical Concepts, Inc. research and development expense for fiscal 2023 was $15.44M, a 13.66% increase from fiscal 2022.
- Treace Medical Concepts, Inc. research and development expense for fiscal 2022 was $13.58M, a 33.12% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.38M 10-Q · filed 2026-08-07 | $9.00M 10-Q · filed 2026-08-07 | $13.54M derived: sum of 3 quarters · filed 2026-08-07 | $18.22M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $4.62M 10-Q · filed 2026-05-08 | $9.16M derived: sum of 2 quarters · filed 2026-05-08 | $13.84M derived: sum of 3 quarters · filed 2026-05-08 | $19.34M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $9.22M derived: sum of 2 quarters · filed 2026-02-27 | $14.72M derived: sum of 3 quarters · filed 2026-08-07 | $20.28M 10-K · filed 2026-02-27 |
| 2025-09-30 | $4.68M 10-Q · filed 2025-11-06 | $10.18M derived: sum of 2 quarters · filed 2026-08-07 | $15.74M 10-Q · filed 2025-11-06 | $20.95M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $5.50M 10-Q · filed 2026-08-07 | $11.06M 10-Q · filed 2026-08-07 | $16.27M derived: sum of 3 quarters · filed 2026-08-07 | $21.23M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $5.56M 10-Q · filed 2026-05-08 | $10.77M derived: sum of 2 quarters · filed 2026-05-08 | $15.73M derived: sum of 3 quarters · filed 2026-05-08 | $20.89M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $10.17M derived: sum of 2 quarters · filed 2026-02-27 | $15.33M derived: sum of 3 quarters · filed 2026-02-27 | $20.59M 10-K · filed 2026-02-27 |
| 2024-09-30 | $4.96M 10-Q · filed 2025-11-06 | $10.12M derived: sum of 2 quarters · filed 2025-11-06 | $15.38M 10-Q · filed 2025-11-06 | $19.53M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $5.16M 10-Q · filed 2025-08-07 | $10.42M 10-Q · filed 2025-08-07 | $14.57M derived: sum of 3 quarters · filed 2026-02-27 | $18.92M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $5.26M 10-Q · filed 2025-05-08 | $9.41M derived: sum of 2 quarters · filed 2026-02-27 | $13.76M derived: sum of 3 quarters · filed 2026-02-27 | $17.29M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $8.50M derived: sum of 2 quarters · filed 2026-02-27 | $12.03M derived: sum of 3 quarters · filed 2026-02-27 | $15.44M 10-K · filed 2026-02-27 |
| 2023-09-30 | $4.35M 10-Q · filed 2024-11-05 | $7.88M derived: sum of 2 quarters · filed 2024-11-05 | $11.29M 10-Q · filed 2024-11-05 | $15.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.53M 10-Q · filed 2024-08-06 | $6.94M 10-Q · filed 2024-08-06 | $10.69M derived: sum of 3 quarters · filed 2025-02-27 | $14.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.41M 10-Q · filed 2024-05-07 | $7.16M derived: sum of 2 quarters · filed 2025-02-27 | $10.96M derived: sum of 3 quarters · filed 2025-02-27 | $13.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.55M derived: sum of 2 quarters · filed 2025-02-27 | $10.53M derived: sum of 3 quarters · filed 2025-02-27 | $13.58M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.80M 10-Q · filed 2023-11-09 | $6.78M derived: sum of 2 quarters · filed 2023-11-09 | $9.84M 10-Q · filed 2023-11-09 | $13.21M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $2.98M 10-Q · filed 2023-08-09 | $6.04M 10-Q · filed 2023-08-09 | $9.41M derived: sum of 3 quarters · filed 2024-02-27 | $11.95M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $3.05M 10-Q · filed 2023-05-09 | $6.43M derived: sum of 2 quarters · filed 2024-02-27 | $8.97M derived: sum of 3 quarters · filed 2024-02-27 | $11.39M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $5.91M derived: sum of 2 quarters · filed 2024-02-27 | $8.34M derived: sum of 3 quarters · filed 2024-02-27 | $10.20M 10-K · filed 2024-02-27 |
| 2021-09-30 | $2.54M 10-Q · filed 2022-11-09 | $4.96M derived: sum of 2 quarters · filed 2022-11-09 | $6.83M 10-Q · filed 2022-11-09 | $8.75M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-06-30 | $2.42M 10-Q · filed 2022-08-10 | $4.29M 10-Q · filed 2022-08-10 | $6.21M derived: sum of 3 quarters · filed 2023-03-08 | $7.72M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-03-31 | $1.87M 10-Q · filed 2022-05-06 | $3.79M derived: sum of 2 quarters · filed 2023-03-08 | $5.30M derived: sum of 3 quarters · filed 2023-03-08 | $6.28M derived: sum of 4 quarters · filed 2023-03-08 |
| 2020-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $3.43M derived: sum of 2 quarters · filed 2023-03-08 | $4.42M derived: sum of 3 quarters · filed 2023-03-08 | $5.85M 10-K · filed 2023-03-08 |
| 2020-09-30 | $1.51M 10-Q · filed 2021-11-04 | $2.49M derived: sum of 2 quarters · filed 2021-11-04 | $3.92M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $982.00K 10-Q · filed 2021-08-05 | $2.42M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $1.43M 10-Q · filed 2021-05-25 | |||
| 2019-12-31 | $5.07M 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |